On 5/1/26, Rithm Capital Corp's Reset Rate Series D Cumulative Preferred Stock (Symbol: RITM.PRD) will trade ex-dividend, for its quarterly dividend of $0.4375, payable on 5/15/26. As a percentage of RITM.PRD's recent share price of $25.17, this dividend works out to approximat
On 5/1/26, Rithm Capital Corp's Reset Rate Series D Cumulative Preferred Stock (Symbol: RITM.PRD) will trade ex-dividend, for its quarterly dividend of $0.4375, payable on 5/15/26. As a percentage of RITM.PRD's recent share price of $25.17, this dividend works out to approximat
On 5/1/26, Rivernorth Opportunities Fund Inc's 6.00% Series A, Perpetual Preferred Stock (Symbol: RIV.PRA) will trade ex-dividend, for its quarterly dividend of $0.375, payable on 5/15/26. As a percentage of RIV.PRA's recent share price of $22.75, this dividend works out to app
On 5/1/26, Rivernorth Opportunities Fund Inc's 6.00% Series A, Perpetual Preferred Stock (Symbol: RIV.PRA) will trade ex-dividend, for its quarterly dividend of $0.375, payable on 5/15/26. As a percentage of RIV.PRA's recent share price of $22.75, this dividend works out to app
On 5/1/26, RIVERNORTH/DOUBLELINE Strategic Opportunity Fund's 6.00% Series C Term Preferred Stock (Symbol: OPP.PRC) will trade ex-dividend, for its quarterly dividend of $0.15, payable on 5/15/26. As a percentage of OPP.PRC's recent share price of $10.30, this dividend works ou
On 5/1/26, RIVERNORTH/DOUBLELINE Strategic Opportunity Fund's 6.00% Series C Term Preferred Stock (Symbol: OPP.PRC) will trade ex-dividend, for its quarterly dividend of $0.15, payable on 5/15/26. As a percentage of OPP.PRC's recent share price of $10.30, this dividend works ou
Obesity drug giant Eli Lilly on Thursday reported a monster first quarter, fortifying our conviction to stick with the stock after a period of sluggishness. Revenue in the three months ended in March jumped 56% from a year ago to $19.8 billion, trouncing the LSEG consensus of $17.6 billion. Adjusted earnings per share totaled $8.55, more than doubling on an annual basis and crushing the $6.66 cons...
Obesity drug giant Eli Lilly on Thursday reported a monster first quarter, fortifying our conviction to stick with the stock after a period of sluggishness. Revenue in the three months ended in March jumped 56% from a year ago to $19.8 billion, trouncing the LSEG consensus of $17.6 billion. Adjusted earnings per share totaled $8.55, more than doubling on an annual basis and crushing the $6.66 consensus, according to LSEG. LLY 1Y mountain Eli Lilly's stock performance over the past 12 months. Shares surged about 10% on Thursday. The stock came into the day down 21% for the year and roughly 23% off its late November all-time closing high of $1,110. The weakness in the stock was tied to a broader rotation away from the healthcare sector, and broader questions about the competitive dynamics in the booming GLP-1 market. Bottom line Lilly knocked it out of the park. As if the massive top and bottom-line beats were not enough, the drugmaker raised its full-year guidance for revenue, operating profitability and earnings per share. "This is one of the greatest pharma stories," Jim Cramer said Thursday. A big reason why Lilly's results are so impressive: It's doing this despite weaker realized drug prices in the U.S., partially stemming from most favored nation agreements with the Trump administration in exchange for Medicare access. Competition from Novo Nordisk , the maker of Ozempic for diabetes and Wegovy for weight loss, is another factor. Regardless, Eli Lilly CEO David Ricks has insisted his company will be able to overcome lower prices with higher volumes — and that's what is happening. In the first quarter, pricing fell 7% in the U.S., but volumes jumped 49% driven by its injectable GLP-1s, Zepbound for obesity and Mounjaro for type 2 diabetes. (Both drugs share the active ingredient of tirzepatide.) The dynamic was actually even more pronounced on a worldwide basis, with pricing down 13% and volumes up 65%. China was a big driver of the weaker prices globally. Mounj...
KION GROUP AG press release ( KIGRY ): Q1 EPS of €0.69. Revenue of €2,771.4M (-0.6% Y/Y). More on KION GROUP AG KION GROUP AG 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for KION GROUP AG Dividend scorecard for KION GROUP AG Financial information for KION GROUP AG
KION GROUP AG press release ( KIGRY ): Q1 EPS of €0.69. Revenue of €2,771.4M (-0.6% Y/Y). More on KION GROUP AG KION GROUP AG 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for KION GROUP AG Dividend scorecard for KION GROUP AG Financial information for KION GROUP AG
It has been a volatile first one-third of 2026, with stocks rebounding a bit in April after a sharp decline in the first quarter. If volatility and uncertainty have made it hard to determine where markets are headed, investors may find some guidance by learning what billionaire hedge fund managers are doing. Image source: Getty Images. Continue reading
It has been a volatile first one-third of 2026, with stocks rebounding a bit in April after a sharp decline in the first quarter. If volatility and uncertainty have made it hard to determine where markets are headed, investors may find some guidance by learning what billionaire hedge fund managers are doing. Image source: Getty Images. Continue reading
BlackRock COO Rob Goldstein has drawn a line through the software-as-a-service (SaaS) universe, and investors holding tech-heavy portfolios should pay attention. Speaking on Bloomberg’s Odd Lots with host Tracy Alloway, the head of BlackRock (NYSE:BLK) Solutions and the Aladdin platform argued that a specific slice of SaaS faces structural disruption from generative AI: the layer ... BlackRock’s R...
BlackRock COO Rob Goldstein has drawn a line through the software-as-a-service (SaaS) universe, and investors holding tech-heavy portfolios should pay attention. Speaking on Bloomberg’s Odd Lots with host Tracy Alloway, the head of BlackRock (NYSE:BLK) Solutions and the Aladdin platform argued that a specific slice of SaaS faces structural disruption from generative AI: the layer ... BlackRock’s Rob Goldstein: ‘Convenience-Layer’ SaaS Companies Are ‘In Trouble’ From AI
A California man recently filed a lawsuit against Morgan Stanley accusing the Wall Street giant of improperly enabling the collection of user data from its website through third-party tracking tools. It is at least the third such case Taajudin Elmarouk has brought against a large corporation. Elmarouk is seeking class-action certification in the Morgan Stanley lawsuit, which was filed April 23, as...
A California man recently filed a lawsuit against Morgan Stanley accusing the Wall Street giant of improperly enabling the collection of user data from its website through third-party tracking tools. It is at least the third such case Taajudin Elmarouk has brought against a large corporation. Elmarouk is seeking class-action certification in the Morgan Stanley lawsuit, which was filed April 23, as well as similar litigation targeting Fidelity Investments, filed April 2, and cosmetics company Estée Lauder filed Dec. 23, 2025.
JoAnne Feeney, portfolio manager & partner at Advisors Capital Management. joins Scarlet Fu on "Bloomberg Markets." Meta Platforms shares plunged by the most in six months after the company raised its spending outlook for the year, reigniting fears that the historic levels of investment that CEO Mark Zuckerberg is making to catch up in the artificial intelligence race won’t pay off. (Source: Bloom...
JoAnne Feeney, portfolio manager & partner at Advisors Capital Management. joins Scarlet Fu on "Bloomberg Markets." Meta Platforms shares plunged by the most in six months after the company raised its spending outlook for the year, reigniting fears that the historic levels of investment that CEO Mark Zuckerberg is making to catch up in the artificial intelligence race won’t pay off. (Source: Bloomberg)
Earnings Call Insights: A. O. Smith (AOS) Q1 2026 Management View “North America sales increased 1% to $753 million and Rest of World sales decreased 11% to $201 million, resulting in total company first quarter sales of $946 million, a decrease of 2%.” (President, CEO & Director Stephen Shafer)
Earnings Call Insights: A. O. Smith (AOS) Q1 2026 Management View “North America sales increased 1% to $753 million and Rest of World sales decreased 11% to $201 million, resulting in total company first quarter sales of $946 million, a decrease of 2%.” (President, CEO & Director Stephen Shafer)